{"disease":{"id":"metastatic-alk-non-small-cell-lung-cancer","name":"Metastatic ALK+ Non Small Cell Lung Cancer","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:31:21.551Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":0,"pipeline_drug_count":1,"trial_count":0},"drugs":{"marketed":[],"pipeline":[{"drug_id":"lorviqua","indication_name":"Metastatic ALK+ Non Small Cell Lung Cancer","indication_type":"pipeline","phase":"preclinical","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lorviqua","generic_name":"lorviqua","company_name":"Pfizer Inc.","drug_phase":"preclinical","molecular_target":"Tyrosine-protein kinase FRK, ALK tyrosine kinase receptor, Activated CDC42 kinase 1","drug_class":"As provided in real world practice","quality_score":0,"revenue":null,"mechanism":"As provided in real world practice"}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[{"nct_id":"NCT05599412","title":"Post Marketing Surveillance(PMS) Study of Lorviqua in Korea","phase":"","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"Pfizer","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}